Changes of number of stock units and votes in Artimplant AB

With reference to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980), it is hereby announced that the new issue of Series B stock units during March 2012 has led to the below changes in the number of stock units and votes in Artimplant AB.

Before the new issue: Series A stock units 575,000, Series B stock units 117.914.580, total number of stock units 118.489.580 and the number of votes 123.664.580.

Increase due to new issue: Series B stock units 395.492.676.
After the new issue: Series A stock units 575.000, Series B stock units 513.407.256, total number of stock units 513.982.256 and total number of votes 519.157.256.

 
For further information, please contact:

Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 31 746 56 00, +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

 
Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on March 30, 2012 at 4 PM (Swedish time).